Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02898649

Safety and Efficacy of Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer Clinical Trial

Clinical Trial Summary

Pancreatic cancer is 5th leading cause of cancer-related death in Korea. It has a dismal prognosis with very low 5-year survival rate, about 5%. Only 10% of pancreatic cancer patients is diagnosed in operable status. So, most of patients could not be treated with curative resection.

Locally advanced pancreatic cancer (LAPC) is defined by defined as surgically unresectable due to vascular encasement (e.g. celiac trunk or superior mesenteric artery) by tumor, but have no evidence of distant metastases. In LAPC patients, systemic chemotherapy with/without radiotherapy was used as a standard therapy, but therapeutic response was very poor. Only less than 30% of patients showed treatment response, and median survival of LAPC patient was only 9 months. Thus, more effective treatment modality is needed for LAPC patients.

Irreversible electroporation (IRE) is a soft tissue ablation technique using ultra short but strong electrical fields to create permanent and hence lethal nanopores in the cell membrane, to disrupt the cellular homeostasis. IRE does not cause thermally induced necrosis and has tissue selectivity, so adjacent tissue or vascular structures can be preserved.

Several clinical trials using IRE were performed to liver, kidney or lung cancer patients. We will operate IRE procedure to LAPC patients who were previously received standard therapy but showed no response, using NanoKnife IRE device. We will investigate treatment response and safety of IRE.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02898649
Study type Interventional
Source Yonsei University
Contact Seung Min Bang, MD
Phone +82 2 2228 1995
Email BANG7028@yuhs.ac
Status Recruiting
Phase N/A
Start date December 2015
Completion date August 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Completed NCT01628458 - Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT04276857 - Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer N/A
Not yet recruiting NCT05988372 - Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2
Completed NCT03126435 - EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Phase 3
Completed NCT02035072 - Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. Phase 2
Enrolling by invitation NCT01063192 - A Study of Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT06429904 - Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03885219 - Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03468335 - 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy Phase 3
Not yet recruiting NCT03443921 - Divestment for Artery-involved Pancreatic Cancer N/A
Recruiting NCT03257033 - Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Phase 3
Completed NCT02578732 - FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Phase 2
Recruiting NCT04789980 - Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
Completed NCT00644618 - Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Phase 3
Recruiting NCT03682289 - Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Phase 2
Terminated NCT02404363 - Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy Phase 3
Active, not recruiting NCT06353581 - Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX Phase 2
Not yet recruiting NCT03815461 - Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer Phase 2